Ceva Animal Health launches Tulaven

Animal Health

Ceva Animal Health has launched Tulaven, which contains tulathromycin, to bolster its range of treatments for bovine respiratory disease (BRD).

As well as being able to treat infectious bovine keratoconjunctivitis and porcine respiratory disease, Tulaven is authorised for the treatment and metaphylaxis of BRD. Also, the therapy is approved for early stages of infectious pododermatitis in sheep.

“Ceva Animal Health launches Tulaven.“

Managing Director, Ceva Animal Health UK & Ireland, Cuneyt Seckin, stated: “Ceva has been developing its expertise in the treatment of BRD for many years, with a wide range of treatment options and autogenous vaccines available for vets. The launch of Tulaven is the next addition to this range, enabling us to offer even more support to vets and farmers.”

See all the latest jobs in Animal Health
Return to news